ClinicalTrials.gg

Program

AMG 127

A development code.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Amgen.

Furthest: phase 1, since May 11, 20261 company-led study, 1 open or runningNext primary completion: Oct 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen11 open or runningphase 1since May 11, 2026May 11, 2026Oct 2, 2027phase 1 · NCT07590193

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 11, 2026First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT07590193 · 162 planned · United States

Ahead

  1. Oct 2, 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07590193

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07590193Diabetes Mellitus, Type 2 · United States1RecruitingOct 2, 2027162

How it is read

Names in the registry

  • “AMG 127”, 1 entry

Codes read as this program: AMG127.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.